Prime Medicine, Inc. (PRME) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $63.03M | -65.5% |
| 2024 | $182.48M | +338.9% |
| 2023 | $41.57M | -77.8% |
| 2022 | $187.62M | +1.2% |
| 2021 | $185.42M | +401.5% |
| 2020 | $36.98M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $63.03M | -65.5% |
| 2024 | $182.48M | +338.9% |
| 2023 | $41.57M | -77.8% |
| 2022 | $187.62M | +1.2% |
| 2021 | $185.42M | +401.5% |
| 2020 | $36.98M | — |